The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.
Geoffrey Thomas Gibney
Research Funding - Bristol-Myers Squibb
Omid Hamid
Consultant or Advisory Role - Incyte (U)
Tara C. Gangadhar
No relevant relationships to disclose
Jose Lutzky
No relevant relationships to disclose
Anthony J. Olszanski
No relevant relationships to disclose
Thomas Gajewski
Consultant or Advisory Role - AbbVie; Amgen; Bayer; Boehringer Ingelheim; Dendreon; Jounce Therapeutics; Roche/Genentech
Research Funding - Bristol-Myers Squibb; Incyte; Merck; Ono Pharmaceutical ; Roche/Genentech
Bartosz Chmielowski
Consultant or Advisory Role - Genentech; Merck
Honoraria - Amgen; Bristol-Myers Squibb; Genentech; Merck; Prometheus
Peter D. Boasberg
No relevant relationships to disclose
Yufan Zhao
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Robert Charles Newton
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Peggy A Scherle
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Jill Bowman
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Janet Maleski
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Lance Leopold
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Jeffrey S. Weber
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb